By Steve Elliott
Oregon has "temporarily" halted issuance of state licenses for industrial hemp cultivation, pointing to policy issues that emerged during the inaugural year of the program.
The decision doesn't impact those currently licensed to grow hemp in the state, Oregon Department of Agriculture officials said on Tuesday, reports Noelle Crombie of The Oregonian. The decision is effective immediately, coming at the end of the current growing season.
The problems will be resolved in time for next year's growing season -- or at least, officials hope so, according to Lindsay Eng, who oversees the state's hemp program.
The decision to stop issuing licenses isn't tied to concerns raised by marijuana growers who don't want hemp planted near their crops, according to Eng. Marijuana farmers say hemp production near their cops poses a risk for cross pollination and threatens the quality of their cannabis crop.
Eng said the Department of Agriculture needs to address a new law reducing from three years to one the licenses for hemp production. The change takes effect on January 1, 2016.
"We just didn't feel it was prudent to continue issuing new three-year licenses when so much might change," she said. Eng said the 2009 hemp law is "very short and general" and doesn't address the growing practices of farmers currently licensed to cultivate the crop.
Clover Leaf University, a Department of Higher Education approved occupational program focused on the cannabis industry, and Flowering H.O.P.E. Foundation, a Colorado based nonprofit, on Monday announced a joint program to conduct a clinical study on the high-CBD epilepsy therapy known as Haleigh's Hope™.
The study, scheduled to begin this fall, will examine the safety of Haleigh's Hope for use in treating childhood epilepsy. The study is slated to work with 50 patients over the course of the trial. According to the strain's developer Jason Cranford, Haleigh's Hope has been used effectively to reduce the symptoms of epilepsy in more than 300 children nationwide.
Cranford is founder of the Flowering H.O.P.E. Foundation, a health care associate for the Society for Cannabis Clinicians, and an expert botanist who specializes in the organic cultivation of medical grade cannabis and the development of highly medicinal cannabis infused products. Over the past four years, Cranford has successfully bred and produced a 95 percent CBD plant that has been verified through two independent labs. He has developed several CBD rich infused products including Haleigh's Hope™ and Cannatol™.
By Steve Elliott
In yet another demonstration of the broad usefulness of cannabis for a range of diseases and injuries, Israeli scientists have discovered that marijuana can be effectively used in healing broken bones, and possibly in treating skeletal illnesses.
Researchers from Tel Aviv University published in the Journal of Bone and Mineral Research a study that showed cannabis includes a component which enhances the healing process of fractured bones, reports RT.com.
Cannabidiol, a non-psychoactive component of marijuana, sped up the healing process in broken leg bones of trial rats with mid-femoral fractures, the study found.
"While there is still a lot of work to be done to develop appropriate therapies, it is clear that is is possible to detach a clinical therapy objective from the psychoactivity of cannabis," said Dr. Yankel Gabet of Tel Aviv University's Bone Research Laboratory. "CBD, the principal agent in our study, is primarily anti-inflammatory and has no psychoactivity."
Scientists tested two groups of rats, one with both CBD and THC, and the other with CBD only. "We found CBD alone to be sufficiently effective in enhancing fracture healing," Gabet said, in a statement which seems to imply that THC was also effective.
“Other studies have also shown CBD to be a safe agent, which leads us to believe we should continue this line of study in clinical trials to assess its usefulness in improving human fracture healing,” Gabet said.
Hemp Health Inc., a maker of cannabidiol (CBD) products, on Tuesday introduced THC Buzzkill, a patent-pending CBD supplement that counteracts the "high" of marijuana.
Sold as an oral spray, THC Buzzkill absorbs into the bloodstream rapidly and lessens the psychoactive effects of THC using all-natural ingredients, according to Hemp Health, which called THC Buzzkill is the first supplement designed for marijuana users who need to sober up quickly.
"When you have things to do and places to be, being stoned usually doesn't help you get it all done," said Katarina Maloney, president of Hemp Health Inc. "For marijuana users who smoke too much, react strangely to a new strain, or just need to get into a more functional state, THC Buzzkill does exactly what the name implies.
"Think of it as fire extinguisher for marijuana emergencies," Maloney said.
THC Buzzkill's primary ingredients come from high-CBD, low-THC cannabis. Kosher, vegan and non-GMO, the cannabis is sourced from sustainable farms in Germany, Denmark and other European countries.
THC Buzzkill is legal all 50 states and 42 countries, according to Hemp Health.
THC Buzzkill pilot users report that the tincture lessens the effects of marijuana within 15 minutes. The supplement does not remove chemical traces of THC from the human body, and it does not make it safe for the marijuana user to drive an automobile or operate machinery, according to the company. Taking THC Buzzkill prior to consuming marijuana will not block the effects.
Water soluble formulations of cannabidiol (CBD), combined with Ayurvedic herbs, are now available for wholesale, private label, bulk and licensing opportunities from an Encinitas, California-based company.
Evolved Ayurvedic Discoveries, Inc. (EAD Labs), nutraceutical company, is announcing with their launch, "an intention to partner with companies that share a similar mission of providing the most effective and safe holistic health solutions on the planet."
“Side by side, our water soluble CBD, BioCBD™, is head and shoulders above every other CBD oil product in terms of bioavailability,” said EAD Labs CEO and cofounder James Sol Radina. “We are excited to announce our revolutionary delivery technology to the world.
"We are looking for companies who want to join us in evolving not only the Medical Marijuana industry, but the entire healthcare industry as well,” Radina said.
The technology and process behind EAD's products was devised by company cofounder and Chief Scientific Officer Dr. Mewa Singh, the inventor of Hybrid-Nanoengineering™, "possibly the single biggest advancement in nutraceuticals," according to the company.
Dr. Singh has spent almost 30 years developing and launching products for diagnostics, vaccines, nutraceuticals and nanomedicines. He has developed more than 145 nanomedicines for use as pharmaceuticals, nutraceuticals and agrochemicals, according to EAD.
FDA and NIDA officials express support for ending NIDA’s DEA-mandated monopoly on marijuana available for research purposes
By Steve Elliott
At a Wednesday hearing, Senators Cory Booker and Kirsten Gillibrand pressed federal officials to eliminate political barriers that are preventing research on the potential medical benefits of marijuana. The hearing, “Cannabidiol: Barriers to Research and Potential Medical Benefits,” was held by the Senate Caucus on International Narcotics Control.
Officials from the National Institute on Drug Abuse (NIDA) and the Food and Drug Administration (FDA) echoed the Senators’ concerns and expressed support for removing barriers to research that have been created by the Drug Enforcement Administration (DEA).
NIDA has a DEA-mandated monopoly on the supply of marijuana available for research purposes, which is grown at the University of Mississippi. Researchers have repeatedly criticized the DEA for refusing to license additional marijuana producers, which they say is preventing the study of marijuana’s medical benefits and the development of marijuana-based medicines.
They have also criticized the poor quality and low potency of the scant marijuana that is currently available, which they say further hinders meaningful research. A DEA administrative law judge ruled that licensing additional producers would be in the public interest, but the DEA has refused to follow the non-binding ruling.
CBD Sourced from High-Quality, Colorado-Grown Organic Hemp Flowers
Mary's Nutritionals on Tuesday announced that its Elite CBD™ products, including gels, compounds, Muscle Freeze and Remedy Oil, are now available for nationwide online purchase and shipping via marysnutritionals.com.
Mary's Elite CBD™ is derived from Elite Botanicals' Colorado-grown, 100 percent organic and natural industrial hemp cannabis plants.
"Mary's is committed to providing products made from plants selected for their optimal cannabinoid content so we can provide the best value to our customers," said Nicole Smith, Mary's Nutritionals CEO. "Plants with a higher concentration of quality CBD deliver more bang for the buck."
Elite Botanicals is a family-run organic hemp farm that produces Elite CBD plants in full compliance with Colorado Department of Agriculture, the 2014 Farm Bill and the pending Industrial Hemp Farming Act of 2015.
"We receive calls and emails every day from individuals across the country looking for high-quality CBD options," said Smith. "With Elite Botanicals' unique industrial hemp, we are now able to create new products with the benefits of whole plant-derived CBD that can be distributed to everyone in need—regardless of where they live."
• Mary's Elite CBD™ Gel Pen is the perfect resource for quick, discreet delivery of CBD. Mary's proprietary dispenser pen contains 50-2mg doses of CBD Gel. Users apply it to the wrist, ankle, temples, or any other veinous area. Contains 100mg CBD.
The U.S. Senate Caucus on International Narcotics Control will hold a hearing Wednesday morning on cannabidiol (CBD), a component of marijuana being used in the treatment of seizure disorders and other medical conditions, and federal obstacles to studying its efficacy.
The hearing, “Cannabidiol: Barriers to Research and Potential Medical Benefits” will be led by Sens. Charles Grassley (R-IA) and Diane Feinstein (D-CA), who have long been opponents of efforts to reform federal marijuana laws.
Sens. Cory Booker (D-NJ) and Kirsten Gillibrand (D-NY) have been invited to participate. They are sponsors of the CARERS Act, bipartisan legislation that would resolve the tension between state and federal marijuana laws.
The hearing is expected to focus on the use of CBD in the treatment of seizure disorders rather than whole-plant medical marijuana and the many other medical conditions for which doctors frequently recommend it. It is also expected to focus on federally regulated distribution channels rather than state-regulated medical marijuana providers.
WHAT: Hearing on CBD research and efficacy
WHEN: Wednesday, June 24, 9:30 a.m. ET
WHERE: Dirksen Senate Office Building, Room 226, Washington, D.C.
WHO: Dr. John Brad Ingram, child neurologist, University of Mississippi
Dr. Tom Minahan, emergency physician and parent of child with seizure disorder
Joseph Rannazzisi, deputy assistant administrator, Office of Diversion Control, Drug Enforcement Administration (DEA)
Dr. Kevin Sabet, anti-marijuana activist, Project SAM
Denver, Colorado-based Mary's Pets on Thursday announced the availability of pet-care products made from American cannabidiol (CBD).
"More and more humans are benefitting from cannabinoid medicine. Shouldn't our furry companions also have access to natural relief?" said Nicole Smith, CEO, Mary's Pets, manufacturer of pet-care CBD supplements made from Colorado-grown hemp.
Smith is also CEO and owner of Mary's Nutritionals, a CBD supplement company using the same hemp-based cannabinoids for people, and Mary's Medicinals, a cannabis company best known for its transdermal patch.
"We've combined our award-winning research and development capabilities and experiences designing medical cannabis products for humans with the latest veterinary science to offer the first transdermal CBD product for our feline, canine and equine friends," Smith said.
The premier offering in the Mary's Pets line is Mary's CBD Gel, a clinically formulated, precisely dosed, transdermal lotion designed to relieve symptoms in mammals of all types.
"Everyone gets sick and feels pain, our pets included," said Noel Palmer, Ph.D., chief scientist, Mary's Pets. "For most animals, CBD can be effectively used as an anti-inflammatory agent, pain-relieving compound and anti-epileptic — just as with humans."
Mary's Pets Gel is enriched with hemp-derived CBD organically grown by Elite Botanicals in northern Colorado. CBD is a non-psychoactive compound that is reported to have anti-convulsive, anti-anxiety, anti-psychotic, anti-nausea, anti-rheumatoid arthritic and sedative properties.
Wana Products on Tuesday announced the launch of WanaCaps XR, a family of extended release cannabis capsules that provide medicinal benefits for up to 12 hours.
Wana Products partnered with Cannabics Pharmaceuticals Inc., a United States-based Drug Development Company with research and development in Israel, that developed the proprietary technology behind the extended release formulation.
WanaCaps XR will be offered in three different formulations: capsules with a 10:1 CBD to THC ratio (WanaCaps XR High CBD Capsules), a 10:1 THC to CBD ratio (WanaCaps XR High THC Capsules), and a balanced formulation with 1:1 THC:CBD ratio (WanaCaps XR THC/CBD Balanced Capsules).
“WanaCaps XR represents the next generation in the evolution of marijuana for the medical community,” said Nancy Whiteman, co-owner of Wana Products. “The extended release formulation enables patients to dose once or twice daily so they can get on with their lives without the constant need to be thinking about re-dosing. Additionally, WanaCaps XR are formulated to be highly bio-available so patients feel the therapeutic impact quickly.”
“The new capsules also address one of the major concerns of cannabis patients, which is that the initial high peak of cannabinoid activity soon after administration which can cause uncomfortable side effects such as disorientation and dizziness,” Whiteman said. “Instead, with WanaCaps XR, patients experience a long-lasting, stable effect for up to 10 hours without the ups and downs. Overall, it’s just a much better experience for patients.”
As the possibilities for cannabis-based treatments continue to make headlines in the medical world, One World Cannabis, a medical-cannabis research company, has announced that the initial results of its landmark study on treating multiple myeloma with cannabis-based solutions were extremely promising. After a series of tests using cannabis-based treatments, researchers were able to eradicate 60 percent of multiple myeloma cells.
The disease is one of the most deadly hematologic cancers and individuals diagnosed with the disease often have about a 50 percent survival rate.
OWC Pharmaceutical Research Corp. on Wednesday announced that its wholly owned subsidiary, One World Cannabis Ltd., an Israel-based developer of cannabinoid-based therapies targeting a variety of different indications, has received the first basic science study (lab) results on the effect of several combination of cannabidiol (CBD) and tetrahydrocannabinol (THC) on multiple myeloma cell line RPMI8226.
Based on the results, One World Cannabis will submit the clinical trial protocol to the IRB (Helsinki committee). The company expects to receive institutional review board approval for the study within 6-9 weeks.
The OWC multiple myeloma study was done by three repetitive tests on the effect of cannabis extract with various combination ratios of THC/CBD and pure THC and CBD (50 percent concentration). The results present more than 60 percent malignant cell death. More results of pure THC and CBD are under further analysis.
By Steve Elliott
Kalel Santiago of Puerto Rico is just 9 years old, but he hasn't had an easy nine years. At just 10 months old, he was diagnosed with the rare childhood cancer neuroblastoma, and he spent more than two years going through surgery, chemotherapy, and radiation treatments. Then he was diagnosed with severe, non-verbal autism.
"While he was in the hospital, we noticed he didn't speak at all and had some behavior that wasn't right, like hand flapping, and walking on his toes," said Abiel Gomez Santiago, Kalel's father, from their home in Aguada, reports Beth Greenfield at Yahoo Parenting. "But we waited until he was 3 and cancer-free to look at his behavior."
Abiel and his wife Gladys did a crash course in autism. They tried various therapies, and eventually happened upon a treatment that would change their lives: hemp oil, rich in cannabidiol (CBD), which has anecdotally been shown to dramatically ease symptoms of both epilepsy and autism.
They began giving their son twice daily doses of a CBD oral spray, and the results were startling -- Kalel started talking in just two days after a lifetime of silence.
“He surprised us in school by saying the vowels, A-E-I-O-U. It was the first time ever,” Abiel said. “You can’t imagine the emotion we had, hearing Kalel’s voice for the first time. It was amazing.
By Steve Elliott
Florida regulators said they expect to provide access to a strain of non-euphoric marijuana for medical purposes by the end of this year after a Tallahassee judge last week dismissed the final challenge to the long-awaited rule.
The Florida Department of Health is expected to start accepting applications within three weeks from eligible growers within three weeks for the strain of cannabis that is low in THC, the main "high"-inducing component, and high in cannabidiol (CBD), which, like THC, also has medicinal effects, reports Mary Ellen Klas at the Miami Herald.
Growers could start selling to eligible patients who are put on a state-run "compassionate use registry" within months.
"I am one happy legislator," said Rep. Matt Gaetz (R-Shalimar), one of the sponsors of the 2014 bill designed to allow the development and cultivation of the "Charlotte's Web" strain of low-THC cannabis to help patients suffering from epileptic seizures and other ailments. (The clueless legislators passed the law naming a specific strain of low-CBD marijuana, evidently unaware that there are lots of low-CBD medicinal strains, but in the process making the Stanley Brothers -- who control the supply of Charlotte's Web -- very happy.)
By Steve Elliott
A mother in South Carolina is manufacturing cannabis oil, legally. The oil is high in cannabidiol (CBD), a non-psychoactive but medicinal component of marijuana that is now legal in the state under S. 839, which allows for consumable hemp products with less than .3 percent of THC.
"I'm building my company here," said Janel Ralph, reports Molly Grantham at WISTV.com. "I think it'll be up and running in maybe six months. But I'm an optimist. I guess I can't say exactly on the timeline."
Janel's company, Palmetto Synergistic Research, will specialize in CBD oil.
Because of the controversy surrounding marijuana, Ralph is keeping her location secret.
"There will be people who would intentionally try to steal it not knowing that it's hemp," she said. "Criminals could hear I'm manufacturing medical marijuana and think they could take it.
"They wouldn't understand that what I'm making has such a low THC, that even if they took they plants they couldn't smoke it or sell it as marijuana," she said. "You can't get high on what I'm making."
Ralph started it all last year because of her five-year-old daughter, Harmony, who has a genetic condition called lissencephaly. Harmony's brain is missing one of her chromosomes, and she has lots of seizures. Multiple pharmaceuticals didn't work.
Bill is intended to allow access to low-THC marijuana extracts for qualifying seizure patients; House fails to pass amendment to fix major problem
The Texas State House on Monday approved a bill 96-34 intended to allow qualifying patients with intractable seizure conditions to access a marijuana extract containing high levels of cannabidiol, or CBD, and only trace levels of THC. SB 339, sponsored by Sen. Kevin Eltife (R-Tyler), is extremely unlikely to provide patients with relief because it requires doctors to engage in conduct that is prohibited by federal law.
SB 339 previously passed the Senate on May 7. It now heads to Gov. Greg Abbott.
“On a certain level, the legislature should be commended for acknowledging the medical value of marijuana, and it is an historic vote in that sense,” said Heather Fazio, Texas political director for the Marijuana Policy Project (MPP). “Lawmakers missed several opportunities to amend the bill in ways that could have provided real relief to countless Texans. Not a single patient will be helped by this legislation.”
SB 339 requires doctors to “prescribe” marijuana to patients, which exposes doctors to federal criminal sanctions. By contrast, doctors “recommend” medical marijuana or “certify” patients to use medical marijuana in the 23 states with comprehensive medical marijuana laws and the District of Columbia. Unlike “prescriptions,” recommendations and certifications are federally legal and protected under the First Amendment.